Effects of sacubitril‐valsartan in the treatment of chronic heart failure patients with end‐stage renal disease undergoing dialysis

BACKGROUND: The data on the effects of the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril‐valsartan (LCZ696) in chronic heart failure (CHF) patients with end‐stage renal disease (ESRD) requiring dialysis are lacking. This study assessed the efficacy and safety of LCZ696 in CHF patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyan, Huang, Lidong, Tse, Gary, Liu, Tong, Che, Jingjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436793/
https://www.ncbi.nlm.nih.gov/pubmed/37381644
http://dx.doi.org/10.1002/clc.24075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436793/
https://www.ncbi.nlm.nih.gov/pubmed/37381644
http://dx.doi.org/10.1002/clc.24075

Ejemplares similares